T. Rowe Price Japan

Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.

SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.

Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time. Generate Biomedicines has proved that its machine-learning platform can generate new biological molecules with therapeutic value, accelerating the drug discovery process.

Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases. Chroma Medicine was established in 2021 in Cambridge, Massachusetts.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.

Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.

Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI technologies. The company employs a combination of innovative deep neural networks, biophysical simulation techniques, and highly scalable computing infrastructure. This amalgamation of technologies is geared towards achieving remarkable results in molecular generation and property prediction, particularly in the field of drug discovery and molecular design. Established in 2019 and headquartered in South San Francisco, California, Genesis Therapeutics focuses on leveraging innovative AI methodologies to enhance the efficiency and accuracy of molecular research. The company's approach holds promise in revolutionizing how molecules are generated and analyzed, potentially leading to advancements in drug development and related fields.

Imago BioSciences is a clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives. Imago BioSciences was founded in 2012 and is based in Redwood City, California.

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

Flame Biosciences is a clinical-stage company focused on the discovery, development, and commercialization of transformative therapies for cancer and other inflammatory diseases.

PrognomiQ is a technology company that focuses on transforming early disease detection and treatment through multi-omics data. The company generates extensive proteomic, genomic, and metabolomic data to provide insights into complex diseases, aiming to improve patient outcomes. PrognomiQ's innovative approach facilitates the development of advanced test products that enhance the understanding and management of health conditions.

Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

VelosBio is an operator of a clinical-stage biopharmaceutical company intended to develop novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. The company's ROR1-directed therapeutics is a cell-surface protein that is expressed on many hematologic and solid tumors but is absent from normal tissues, making it an attractive tumor-specific therapeutic target and has demonstrated positive preclinical results in tumor models, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers. It was founded in 2017 and headquartered in San Diego, California.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.

Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria to protect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

AveXis , doing business as Novartis Gene Therapies, Inc., is a biotechnology company that specializes in the development and commercialization of gene therapies for patients and families affected by rare and life-threatening neurological genetic diseases. AveXis was acquired by Novartis on May 14, 2018. In 2020, the company was renamed Novartis Gene Therapies.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

AAA is an innovative medicines company focused on the development of targeted radioligand therapies and precision imaging radioligands.

BeiGene, Ltd. is a biotechnology company engaged in the development and commercialization of targeted and immuno-oncology therapies for cancer. Founded in 2010 and based in Beijing, the company operates globally, focusing on addressing significant unmet medical needs across various cancer types. Its commercial portfolio includes treatments such as BRUKINSA for mantle cell lymphoma and Tislelizumab for Hodgkin's lymphoma, alongside other therapies for conditions like breast cancer and multiple myeloma. BeiGene's pipeline features several clinical-stage drug candidates, including Zanubrutinib, an inhibitor targeting Bruton's tyrosine kinase, and Pamiparib, a PARP inhibitor. The company is dedicated to making innovative cancer treatments more affordable and accessible, and it collaborates with various pharmaceutical firms to enhance its research and development efforts.

aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.